GlassScriptPhysician profile
Payam R Yashar
NPI 1144279514
$16,678.66
in general payments reported to CMS, 2019-2025
54 companies · $1,913 in 2025
The $1,913 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,905 · 2020: $1,711 · 2021: $2,698 · 2022: $2,597 · 2023: $3,542 · 2024: $2,313 · 2025: $1,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,393 · Consulting Fee: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,393.05 |
| Consulting Fee | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,549.29 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $2,252.17 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device, General - Therapies |
| Abbott Laboratories | $1,510.87 | 2019-2025 | Gallant, Aveir, Jot Dx |
| Novartis Pharmaceuticals Corporation | $1,295.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,235.77 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $1,018.52 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $922.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $680.23 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $469.17 | 2019-2024 | Farxiga, Wainua, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $467.76 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $421.93 | 2019-2024 | Lifevest |
| Janssen Biotech, INC. | $336.32 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $289.64 | 2023-2025 | Entyvio |
| Alnylam Pharmaceuticals INC. | $270.35 | 2022-2024 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $239.87 | 2021-2023 | Opsumit, Uptravi |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Yashar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.